ResearcherUniversidad San Pablo CEUNo recent work listed
Hipólito J. Durán
Matched on ORCID iD 0009-0007-0135-0562; OpenAlex author ID A5065680469, A5112599532, A5136158614. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper
Papers 6
- Prognostic Value of Lymph Node Status for Actual Long-Term Survival in Resected Pancreatic Cancer. Co-author PMID 32841360↗
- Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections at a High-Volume Center. Co-author DOI 10.1016/j.hpb.2022.05.919↗
- A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2017.08.003↗
- Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. First author DOI 10.1016/j.ejso.2016.01.006↗
- Is arterial infiltration still a criterion for unresectability in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.ciresp.2013.11.001↗
- Alternative arterial reconstruction after extended pancreatectomy. Case report and some considerations of locally advanced pancreatic cancer. Co-author DOI 10.6092/1590-8577/1468↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Riccardo R.C. Caruso · 6 shared papers, 2013–2020 · strength 0.37
- Paper Prognostic Value of Lymph Node Status for Actual Long-Term Survival in Resected Pancreatic Cancer. PMID 32841360↗
- Paper Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections a… DOI 10.1016/j.hpb.2022.05.919↗
- Paper A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic a… DOI 10.1016/j.suronc.2017.08.003↗
- Benedetto Ielpo · 6 shared papers, 2013–2020 · strength 0.37
- Paper Prognostic Value of Lymph Node Status for Actual Long-Term Survival in Resected Pancreatic Cancer. PMID 32841360↗
- Paper Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections a… DOI 10.1016/j.hpb.2022.05.919↗
- Paper A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic a… DOI 10.1016/j.suronc.2017.08.003↗
- Yolanda Quijano · 6 shared papers, 2013–2020 · strength 0.37
- Paper Prognostic Value of Lymph Node Status for Actual Long-Term Survival in Resected Pancreatic Cancer. PMID 32841360↗
- Paper Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections a… DOI 10.1016/j.hpb.2022.05.919↗
- Paper A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic a… DOI 10.1016/j.suronc.2017.08.003↗
- Emilio Vicente · 6 shared papers, 2013–2020 · strength 0.37
- Paper Prognostic Value of Lymph Node Status for Actual Long-Term Survival in Resected Pancreatic Cancer. PMID 32841360↗
- Paper Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections a… DOI 10.1016/j.hpb.2022.05.919↗
- Paper A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic a… DOI 10.1016/j.suronc.2017.08.003↗
- Carlos Plaza Hernandezv · 3 shared papers, 2016–2019 · strength 0.19
- Paper Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections a… DOI 10.1016/j.hpb.2022.05.919↗
- Paper A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic a… DOI 10.1016/j.suronc.2017.08.003↗
- Paper Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenoca… DOI 10.1016/j.ejso.2016.01.006↗
- Rafael Álvarez-Gallego · 1 shared paper, 2017 · strength 0.06
- Antonio Cubillo · 1 shared paper, 2017 · strength 0.06
- Rafael Álvarez · 1 shared paper, 2016 · strength 0.05
- Manuel M. Hidalgo · 1 shared paper, 2016 · strength 0.05
- Almudena Moreno Elola-Olaso · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.